WuXi PharmaTech and Pacific Biomarkers Announce Collaboration
Mar 11, 2014
SHANGHAI and SEATTLE, March 11, 2014 -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D services company with operations in China and the United States, and Pacific Biomarkers (PBI), a premier biomarker laboratory services provider based in Seattle, today announced a biomarker collaboration.
In a new agreement, PBI will provide access to its extensive menu of validated biomarker assays to support WuXi’s integrated clinical trial testing services. This includes bioanalysis and central laboratory services for pharmaceutical and biotech companies performing clinical drug development in China. Biomarkers from PBI complement WuXi’s own biomarker capabilities. PBI has a leading position in biomarkers for cardiovascular diseases, diabetes, obesity, acute kidney injury, musculoskeletal disorders, and inflammation. WuXi offers clinical biomarker services in anatomic pathology, hematology, genomics, and soluble biomarkers focusing on oncology and infectious diseases.
“We are very pleased to reach this agreement with Pacific Biomarkers, which broadens WuXi’s biomarker capabilities in support of our clients’ clinical development,” said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. “Biomarkers are a new and important tool in the development of personalized medicines for many serious diseases.”
“Partnering with WuXi enables us to realize considerable value in our biomarker assets,” said Ronald Helm, CEO of Pacific Biomarkers. “This agreement will allow us to support a broader spectrum of companies developing medicines in Asia with special emphasis on clinical trials performed in China.”
About WuXi PharmaTech
WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.
About Pacific Biomarkers
Pacific Biomarkers is a CAP accredited and CLIA certified biomarker laboratory services provider supporting preclinical and Phase I-IV studies. Since 1989, Pacific Biomarkers has partnered with the Pharmaceutical, Biotech and Diagnostic Manufacturing Industries to provide biomarker laboratory services. Pacific Biomarkers has an established reputation for being on the leading edge of biomarker innovation and provides clients with the best available biomarker testing to produce strong analytical data that meets regulatory compliance and quality assurance standards. PBI’s customized approach which combines scientific consultation, flexibility, and outstanding client services has propelled the company to a prominent position in the rapidly growing pharmaceutical outsourcing industry. With a well-established network of scientific, regulatory, and technology expertise, Pacific Biomarkers is the service provider of choice for many leading international drug manufacturers in the race to bring products to market as quickly and cost effectively as possible.
For more information, please contact:
Ronald Aldridge (for investors)
Director of Investor Relations
Aaron Shi (for the media)
Associate Director, Corporate Communications
Chief Executive Officer